Clinical Trial Update: Study to Assess TOPO2A as a Biomarker for Sensitivity to Doxorubicin/Doxil in Soft Tissue Sarcoma

View source ↗

Summary

The document describes a clinical trial investigating TOPO2A as a biomarker of sensitivity to doxorubicin and Doxil in soft tissue sarcoma. The trial is active …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Soft Tissue Sarcoma

Drugs mentioned

• Doxil (liposomal doxorubicin)
• Doxorubicin (doxorubicin)

Snippet

Sponsor: Fox Chase Cancer Center | Conditions: Soft Tissue Sarcoma | Status: ACTIVE_NOT_RECRUITING